Management of gastro-oesophageal reflux disease symptoms that do not respond to proton pump inhibitors

Current Opinion in Gastroenterology

Volumn 29, Issue 4, 2013, Pages 431-436

  Woodland, Philip ^a   Sifrim, Daniel ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

fundoplication; impedance; proton pump inhibitor; refractory GERD

Indexed keywords

AZD 1386; BACLOFEN; CITALOPRAM; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ADD ON THERAPY; ANALGESIC ACTIVITY; BILE REFLUX; BURNING SENSATION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DYSPEPSIA; EOSINOPHILIC ESOPHAGITIS; ESOPHAGEAL PH MONITORING; ESOPHAGUS BIOPSY; ESOPHAGUS MOTILITY; ESOPHAGUS PAIN; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LIFESTYLE MODIFICATION; NON EROSIVE REFLUX DISEASE; NONCARDIAC CHEST PAIN; PATIENT COMPLIANCE; PHENOTYPE; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLUX ESOPHAGITIS; REVIEW; SMOKING CESSATION; STOMACH FUNDOPLICATION; SUBSTERNAL PAIN; TREATMENT RESPONSE;

ESOPHAGEAL PH MONITORING; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMANS; PROTON PUMP INHIBITORS; TREATMENT FAILURE;

EID: 84879924292     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328360433c     Document Type: Review

References (48)

1. Martinez SD, Malagon IB, Garewal HS, et al. Nonerosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17:537-545.
2. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61:1340-1354.
3. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis-a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012; 36:635-643.
4. Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010; 59:714-721.
5. Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30:1030-1038.
6. Kahrilas PJ, Jonsson A, Denison H, et al. Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression. Am J Gastroenterol 2012; 107:1354-1360.
7. Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10:612-619.
8. Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011; 17:387-394.
9. Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GItract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010; 71:28-34.
10. Shaheen NJ, Denison H, Bjorck K, Silberg DG. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy. Am J Gastroenterol 2013. [Epub ahead of print]. DOI 10.1038/ajg.2012.447
11. Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well defined nonerosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24:747-757.
12. El-Serag HB. Epidemiology of nonerosive reflux disease. Digestion 2008; 78 (Suppl. 1):6-10.
13. Dean BB, Gano ADJ Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-664.
14. Lind T, Havelund T, Carlsson R, et al. Heart burn without oesophagitis:efficacy of omeprazole therapy and features determining the rapeutic response. Scand J Gastroenterol 1997; 32:974-979.
15. Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006; 63:3-12.
16. Veerappan GR, Perry JL, Duncan TJ, et al. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospec-tive study. Clin Gastroenterol Hepatol 2009; 7:420-426; 426.e421-426.e422.
17. Kapel RC, Miller JK, Torres C, et al. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008; 134:1316-1321.
18. Ngo P, Furuta GT, Antonioli DA, Fox VL. Eosinophils in the esophagus-peptic orallergic eosinophilic esophagitis? Case series ofthree patientswith esophageal eosinophilia. Am J Gastroenterol 2006; 101:1666-1670.
19. Garcia-Compean D, Gonzalez Gonzalez JA, Marrufo Garcia CA, et al. Pre-valence of eosinophilic esophagitis in patients with refractory gastroesopha-geal reflux disease symptoms: a prospective study. Dig Liver Dis 2011; 43:204-208.
20. Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model ofendoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol 2011; 106:1439-1445.
21. Dellon ES, Farrell TM, Bozymski EM, Shaheen NJ. Diagnosis of eosinophilic esophagitis after fundoplication for 'refractory reflux': implications for pre-operative evaluation. Dis Esophagus 2010; 23:191-195.
22. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111:1200-1205.
23. Vela MF, Craft BM, Sharma N, et al. Refractory heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am J Gastroenterol 2011; 106:844-850.
24. Ponce J, Ortiz V, Maroto N, et al. High prevalence of heartburn and low acid sensitivity in patients with idiopathic achalasia. Dig Dis Sci 2011; 56:773-776.
25. Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with nonerosive reflux disease. Gut 2009; 58:1185-1191.
26. Savarino E, Marabotto E, Zentilin P, et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from nonerosive reflux disease. Dig Liver Dis 2011; 43:542-547.
27. Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012; 61:501-506.
28. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2005; 3:329-334.
29. Sweis R, Fox M, Anggiansah A, Wong T. Prolonged, wirelesspH-studieshave a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil 2011; 23:419-426.
30. Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesopha-geal refluxforlaparoscopic Nissen fundoplication. Br J Surg 2006; 93:1483-1487.
31. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101:1956-1963.
32. Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008; 103:2446-2453.
33. Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2011; 9:868-874.
34. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99:981-988.
35. Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104:2005-2013.
36. Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-h esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53:2387-2393.
37. Kunsch S, Neesse A, Linhart T, et al. Prospective evaluation of duodenogas-troesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitortherapy. Digestion 2012; 86:315-322.
38. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40mg onceaday isequally effective as lansoprazole 30mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to con-ventional-dose lansoprazole therapy-a prospective, randomized, multicentre study. Aliment Pharmacol Ther 2000; 14:1595-1603.
39. Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50-56.
40. Blackshaw LA, Staunton E, Lehmann A, Dent J. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999; 277:G867-G874.
41. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 h pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52:464-470.
42. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010; 105:1266-1275.
43. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroeso-phageal reflux disease. Gastroenterology 2010; 139:409-417.
44. Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012; 107:1662-1667.
45. Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oeso-phageal pain. Aliment Pharmacol Ther 2011; 33:1113-1122.
46. Krarup AL, Ny L, Gunnarsson J, et al. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scand J Gastroenterol 2013; 48:274-284.
47. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009; 7:1292-1298; quiz 1260.
48. Broeders JA, Roks DJ, Draaisma WA, et al. Predictors ofobjectively identified recurrentrefluxafterprimary Nissen fundoplication. Br J Surg 2011;98:673-679.